Sandoz Raises Guidance As Biosimilars Continue To Drive Growth

CEO Richard Saynor Also Outlines Strategy On US Generics, R&D

 
• By Dave Wallace
  
Sandoz expects high-single-digit sales growth in 2024 (Shutterstock)

More from Earnings

More from Strategy